Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma: A randomized controlled trial

JAMA

Volumn 275, Issue 12, 1996, Pages 931-936

  Israel, Elliot ^a   Cohn, Judith ^b,c   Dubé, Louise ^b   Drazen, Jeffrey M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b ABBOTT LABORATORIES   (United States)

^c ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOXYGENASE INHIBITOR; ZILEUTON;

ARACHIDONIC ACID METABOLISM; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; FORCED EXPIRATORY VOLUME; HUMAN; LIVER FUNCTION TEST; LUNG FUNCTION TEST; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SYMPTOMATOLOGY;

EID: 0029915834     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.275.12.931     Document Type: Article

References (39)

1. Lewis RA, Austen KF, Drazen JM, Clark DA, Marfat A, Corey EJ. Slow reacting substances of anaphylaxis: identification of leukotrienes C-1 and D from human and rat sources. Proc Natl Acad Sci U S A. 1980;77:3710-3714.
2. Owen WF Jr, Soberman RJ, Yoshimoto T, Sheffer AL, Lewis RA, Austen KF. Synthesis and release of leukotriene C4 by human eosinophils. J Immunol. 1987;138:532-538.
3. Brown GP, Monick MM, Hunninghake GW. Human alveolar macrophage arachidonic acid metabolism. Am J Physiol. 1988;254:C809-C815.
4. Drazen JM. Inhalation challenge with sulfido-peptide leukotrienes in human subjects. Chest. 1986; 89:414-419.
5. Adelroth E, Morris MM, Hargreave FE, O'Byrne PM. Airway responsiveness to leukotrienes C4 and D4 and to methacholine in patients with asthma and normal controls. N Engl J Med. 1986;315:480-484.
6. Smith LJ, Greenberger PA, Patterson R, Krell RD, Bernstein PR. The effect of inhaled leukotriene D4 in humans. Am Rev Respir Dis. 1985; 131:368-372.
7. Dahlen SE, Bjork J, Hedqvist P. Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules: in vivo effects with relevance to the acute inflammatory response. Proc Natl Acad Sci U S A. 1981;78:3887-3891.
8. Marom Z, Shelhamer JH, Bach MK, Morton DR, Kaliner M. Slow-reacting substances, leukotrienes C4 and D4, increase the release of mucus from human airways in vitro. Am Rev Respir Dis. 1982; 126:449-451.
9. Laitinen LA, Laitinen A, Haahtela T, Vilkka V, Spur BW, Lee TH. Leukotriene E4 and granulocytic infiltration into asthmatic airways. Lancet. 1993;341:989-990.
10. Fuller RW, Black PN, Dollery CT. Effect of the oral leukotriene D4 antagonist LY171883 on inhaled and intradermal challenge with antigen and leukotriene D4 in atopic subjects. J Allergy Clin Immunol. 1989;83:939-944.
11. Taylor IK, O'Shaughnessy KM, Fuller RW, Dollery CT. Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet 1991;337:690-694.
12. Hui KP, Taylor IK, Taylor GW, et al. Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients. Thorax. 1991;46:184-189.
13. Findlay SR, Barden JM, Easley CB, Glass M. Effect of the oral leukotriene antagonist, ICI 204, 219, on antigen-induced bronchoconstriction in subjects with asthma. J Allergy Clin Immunol. 1992; 89:1040-1045.
14. Friedman BS, Bel EH, Buntinx A, et al. Oral leukotriene inhibitor (MK-886) blocks allergen-induced airway responses. Am Rev Respir Dis. 1993; 147:839-844.
15. Israel E, Juniper EF, Callaghan JT, et al. Effect of a leukotriene antagonist, LY171883, on cold air-induced bronchoconstriction in asthmatics. Am Rev Respir Dis. 1989;140:1348-1353.
16. Israel E, Dermarkarian R, Rosenberg M, et al. The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air. N Engl J Med. 1990;323: 1740-1744.
17. Manning PJ, Watson RM, Margolskee DJ, Williams VC, Schwartz JI, O'Byrne PM. Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4-receptor antagonist. N Engl J Med. 1990;323:1736-1739.
18. Robuschi M, Riva E, Fuccella LM, et al. Prevention of exercise-induced bronchoconstriction by a new leukotriene antagonist (SK&F 104353): a double-blind study versus disodium cromoglycate and placebo. Am Rev Respir Dis. 1992;145:1285-1288.
19. Makker HK, Lau LC, Thomson HW, Binks SM, Holgate ST. The protective effect of inhaled leukotriene receptor D4 receptor antagonist ICI 204,219 against exercise-induced asthma. Am Rev Respir Dis. 1993;147:1413-1418.
20. Israel E, Fischer AR, Rosenberg MA, et al. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis. 1993;148:1447-1451.
21. Christie PE, Smith CM, Lee TH. The potent and selective sulfidopeptide leukotriene antagonist, SK&F 104353, inhibits aspirin-induced asthma. Am Rev Respir Dis. 1991;144:957-958.
22. Dahlen B, Kumlin M, Margolskee DJ, et al. The leukotriene-receptor antagonist MK-0679 blocks airway obstruction induced by bronchial provocation with lysine-aspirin in aspirin-sensitive asthmatics. Eur Respir J. 1993;6:1018-1026.
23. Nasser SM, Bell GS, Foster S, et al. Effect of the 5-lipoxygenase inhibitor ZD2138 on aspirin-induced asthma. Thorax. 1994;49:749-756.
24. National Heart, Lung, and Blood Institute, National Asthma Education Program, Expert Panel Report. Guidelines for the diagnosis and management of asthma. J Allergy Clin Immunol. 1991;88: 425-534.
25. Dykewicz MS, Greenberger PA, Patterson R, Halwig JM. Natural history of asthma in patients requiring long-term systemic corticosteroids. Arch Intern Med. 1986;146:2369-2372.
26. Cloud ML, Enas GC, Kemp J, et al. A specific LTD4/LTE4-receptor antagonist improves pulmonary function in patients with mild, chronic asthma. Am Rev Respir Dis. 1989;140:1336-1339.
27. Israel E, Rubin P, Kemp J, et al. The effect of inhibition of 5-lipoxygenase by zileuton in mild to moderate asthma. Ann Intern Med. 1993;119:1059-1066.
28. Spector SL, Smith LJ, Glass M, and the Accolate Asthma Trialists Group. Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. Am J Respir Crit Care Med. 1994; 150:618-623.
29. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis. 1987;136:225-244.
30. Juniper EF, Guyatt GH, Ferrie PJ, Griffith LE. Measuring quality of life in asthma. Am Rev Respir Dis. 1993;147:832-838.
31. Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemiol. 1994;47:81-87.
32. Chapman KR, Verbeek PR, White JG, Rebuck AS. Effect of a short course of prednisone in the prevention of early relapse after the emergency room treatment of acute asthma. N Engl J Med. 1991;324:788-794.
33. Hui KP, Barnes NC. Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist. Lancet. 1991;337:1062-1063.
34. Gaddy JN, Margolskee DJ, Bush RK, Williams VC, Busse WW. Bronchodilation with a potent and selective leukotriene D4 (LTD4) receptor antagonist (MK-571) in patients with asthma. Am Rev Respir Dis. 1992;146:358-364.
35. Irapens N, Reiss TF, Teahan JA, et al. Acute bronchodilation with an intravenously administered leukotriene D4 antagonist, MK-679. Am Rev Respir Dis. 1993;147:1442-1446.
36. Dahlen B, Margolskee DJ, Zetterstrom O, Dahlen SE. Effect of the leukotriene receptor antagonist MK-0679 on baseline pulmonary function in aspirin sensitive asthmatic subjects. Thorax. 1993; 48:1205-1210.
37. Kane G, Pollice M, Cohn J, Murray J, Fish J, Peters S. Controlled trial of the effect of a 5-LO inhibitor on lung inflammation produced by segmental antigen challenge. J Allergy Clin Immunol. 1994;93:184. Abstract.
38. Johnson HM, Russell JK, Torres BA. Second messenger role of arachidonic acid and its metabolites in interferon-gamma production. J Immunol. 1986;137:3053-3056.
39. Israel E. New agents in asthma treatment-inhibitors of the formation and action of products of the 5-lipoxygenase pathway of arachidonic acid. In: Crommelin DJA, Midha KK, Nagai T, eds. Topics in Pharmaceutical Sciences. Stuttgart, Germany: Scientific Publishers; 1994:89-102.